Content area

Abstract

Background: The international cooperation between GATLA and AHOPCA with the support of St. Jude led to the adoption of the OEPA/COPDAC as a strategy to improve outcomes in high risk (HR) patients with HL. This study also includes the ABVD regimen for intermediate risk (IR) and low risk (LR) patients.

Methods: Patients were stratified by predefined risk assignment. HR was defined as a disease in stages II B, III B, and IV. Modality treatment: LR: ABVD × 4 ± IFRT (20 Gy); IR: ABVD × 6 ± IFRT (20 Gy); and HR: OEPA–COPDAC + IFRT (20/25 Gy). The staging and response were reviewed in a periodic discussion of presentation of cases in the group. Eligibility for radiotherapy: LR patients in partial response (PR) after 4 ABVD and IR patients in PR after 2 ABVD received IFRT. All HR patients received IFRT at 20 (complete response (CR)) or 25 Gy (PR) depending on the response achieved after the first two OEPA cycles.

Results: From November 2012 to June 2022, 203 pediatric patients were enrolled. A total of 171 patients were eligible in this analysis. HR: 98 patients (57.3%), IR: 52 patients (30.4%), and LR: 21 patients (12.3%). More than half of the patients were in stages III and IV and more than half also presented B symptoms. The response evaluation was performed by PET/CT in 147/171 patients (86%). A total of 68/171 patients (40%) did not received radiotherapy. Radiotherapy was omitted in 95% of the LR patients and 70% of the IR patients. The 10-year OS was 95% (90.7–97.6) for the 171 patients and 93% (85.3–96.4) for HR patients. The 10-year EFS was 91% (85.2–94.2) for the 171 patients and 87.8% (79.5–92.9) for HR patients.

Conclusion: The international cooperation made it possible to significantly improve the outcomes of patients with advance disease in Argentina compared with our previous experience (7-PHD-96: COPP–ABV × 6 + IFRT Bulky Disease or PR (20/25 Gy): 5yOS: 85%, 5yEFS: 67%), reduce the number of patients who required radiotherapy, and reproduce the European experience for HR patients in a totally different context.

Details

1009240
Location
Title
Risk-Stratified and Response-Adapted Therapy for Pediatric Hodgkin Lymphoma in Argentina: The GATLA Experience
Author
Veron, David 1   VIAFID ORCID Logo  ; Streitenberger, Patricia 2 ; Matus, Mónica 3 ; Pedro Negri Aranguren 4 ; Costa, Alejandra 5 ; Morell, Daniela 6 ; Terrasa, Sergio 7 ; Castellanos, E Mauricio 8 ; de Alarcon, Pedro 9 ; Dibar, Eduardo 3 ; Makiya, Mónica 3 

 Hospital Universitario Austral Pilar, Buenos Aires Argentina 
 Hospital Italiano de Buenos Aires Buenos Aires Argentina 
 Grupo Argentino Para el Tratamiento de Leucemias Agudas GATLA Buenos Aires Argentina 
 Hospital Materno Infantil San Roque Paraná Entre Ríos, Argentina 
 Hospital de Niños Sor María Ludovica La Plata Argentina 
 Hospital Infantil de Córdoba Córdoba Argentina 
 Departamento de Investigaciones Hospital Italiano de Buenos Aires Buenos Aires Argentina 
 AHOPCA Unidad Nacional Oncología Pediátrica Guatemala City Guatemala 
 Department of Pediatrics University of Illinois College of Medicine Peoria Illinois, USA 
Editor
Suraiya Saleem
Publication title
Volume
2025
Publication year
2025
Publication date
2025
Publisher
John Wiley & Sons, Inc.
Place of publication
New York
Country of publication
United States
ISSN
16879104
e-ISSN
16879112
Source type
Scholarly Journal
Language of publication
English
Document type
Journal Article
Publication history
 
 
Milestone dates
2024-11-20 (Received); 2025-07-05 (Revised); 2025-07-11 (Accepted); 2025-07-26 (Pub)
ProQuest document ID
3236022658
Document URL
https://www.proquest.com/scholarly-journals/risk-stratified-response-adapted-therapy/docview/3236022658/se-2?accountid=208611
Copyright
Copyright © 2025 David Veron et al. Advances in Hematology published by John Wiley & Sons Ltd. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Last updated
2025-08-04
Database
ProQuest One Academic